Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.58 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.58 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039589 | 0.93 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL328050 | 0.93 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL328046 | 0.92 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL13039585 | 0.92 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL2233629 | 0.90 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL2233619 | 0.90 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL13077100 | 0.89 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL278708 | 0.89 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL2955533 | 0.89 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB1 | |
| SCHEMBL13039582 | 0.88 | ITGAV (0.59) | ITGAVITGB3ITGB6ITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825119-B2 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | GALAPAGOS SAS (FR) | 2010-11-02 | — | — | US | disclosed |